{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:55:28Z","timestamp":1777452928056,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Two-drug regimens are increasingly used in clinical practice as switch strategies. We compared the efficacy and safety of two dolutegravir (DTG)-based dual therapies: DTG plus lamivudine (3TC group) versus DTG plus rilpivirine (RPV group).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a multicentre cohort of virologically suppressed (HIV RNA &lt;50 copies\/ml) HIV+ patients switching to DTG+3TC or DTG+RPV we analysed the incidence of virological failures (VF) and treatment discontinuations (TD), as well as their predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We analysed 416 patients, 229 in the 3TC group and 187 in the RPV group. The 3TC group, during 344.4 person-years of follow-up (PYFU), had 10 VF without the emergence of resistance mutations, while 30 patients discontinued the regimen. In the RPV group, during 371.0 PYFU, there were 5 VF (1 developed non-nucleoside reverse transcriptase inhibitor mutations Y181C and E138Q) and 13 TD. The estimated probability of remaining free from VF at 48 weeks showed no significant difference between groups (log-rank 0.172). We found a higher risk of VF in patients with peak viral load &gt;500,000 copies\/ml in both treatment groups (log-rank P=0.004 in each group). The estimated probability of remaining in the study regimen at week 48 was 89.0% with DTG+3TC and 96.1% with DTG+RPV (log-rank 0.015). After adjusting for potential confounders, treatment group was not associated with TD. A significant decrease in total cholesterol was observed at week 48 in both groups while renal function remained unchanged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DTG+RPV and DTG+3TC were compared in populations with different characteristics in clinical practice: both regimens showed good effectiveness and improved lipid profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3270","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T09:08:40Z","timestamp":1538471320000},"page":"63-67","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":34,"title":["A Comparison between two Dolutegravir-Based two-drug Regimens as Switch Strategies in a Multicentre Cohort of HIV-1-Infected Patients"],"prefix":"10.1177","volume":"24","author":[{"given":"Arturo","family":"Ciccullo","sequence":"first","affiliation":[{"name":"Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmaria","family":"Baldin","sequence":"additional","affiliation":[{"name":"Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amedeo","family":"Capetti","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetana","family":"Sterrantino","sequence":"additional","affiliation":[{"name":"Division of Tropical and Infectious Diseases, \u2018Careggi\u2019 Hospital, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"d'Ettorre","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Colafigli","sequence":"additional","affiliation":[{"name":"Infectious Dermatology and Allergology Unit, IFO S. Gallicano Institute (IRCCS), Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Modica","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Siena University Hospital, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Lagi","sequence":"additional","affiliation":[{"name":"Division of Tropical and Infectious Diseases, \u2018Careggi\u2019 Hospital, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Giacomelli","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Vittoria","family":"Cossu","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibilla","family":"Restelli","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"De Luca","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Siena University Hospital, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[{"name":"Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,1,1]]},"reference":[{"key":"bibr1-IMP3270","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1457648"},{"key":"bibr2-IMP3270","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1343300"},{"key":"bibr3-IMP3270","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018758432"},{"key":"bibr4-IMP3270","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"bibr5-IMP3270","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12611"},{"key":"bibr6-IMP3270","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2311-2"},{"key":"bibr7-IMP3270","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018761600"},{"key":"bibr8-IMP3270","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky093"},{"key":"bibr9-IMP3270","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1131"},{"key":"bibr10-IMP3270","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00015-16"},{"key":"bibr11-IMP3270","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001459"},{"key":"bibr12-IMP3270","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12468"},{"key":"bibr13-IMP3270","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001279"},{"key":"bibr14-IMP3270","doi-asserted-by":"publisher","DOI":"10.1177\/2325958218760847"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3270","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3851\/IMP3270","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:38Z","timestamp":1777380758000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.3851\/IMP3270"],"URL":"https:\/\/doi.org\/10.3851\/imp3270","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}